Caris Life Sciences was founded in 2008 with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. With transformative technologies informed by massive amounts of big data, we are revolutionizing healthcare to provide physicians and patients with the highest quality information about their disease – from detecting it early and determining how best to treat it, to developing the next wave of novel therapies.
Caris is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI. The company combines comprehensive molecular profiling with advanced artificial intelligence and machine learning to analyze and unravel the molecular complexity of disease.
Through its large-scale clinico-genomic database and cognitive computing, Caris provides tools for early detection, diagnosis, monitoring, therapy selection, and drug development. The company’s innovations have significantly advanced oncology from an empiric medicine methodology to a precision medicine approach and are being applied across other disease areas including cardiology, neurology, and metabolic conditions.
